Efficacy News and Research

RSS
Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Da Volterra presents promising results of DAV-132 compound for prevention of severe C. diff infections

Da Volterra presents promising results of DAV-132 compound for prevention of severe C. diff infections

Researchers use natural molecule to treat type 2 diabetes

Researchers use natural molecule to treat type 2 diabetes

Leadless pacemaker technology shows promising performance after 12 months

Leadless pacemaker technology shows promising performance after 12 months

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Grape skin extract: A new possibility in diabetes treatment

Grape skin extract: A new possibility in diabetes treatment

New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer

New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Mice study shows specific energy source responsible for performing complex cognitive functions

Mice study shows specific energy source responsible for performing complex cognitive functions

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Finding has implications for understanding cognitive decline in degenerative diseases

Finding has implications for understanding cognitive decline in degenerative diseases

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

BIOTRONIK's Entovis pacemaker system gets FDA approval

BIOTRONIK's Entovis pacemaker system gets FDA approval

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.